Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

NCT04927247 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04927247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04927247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
December 9, 2021
Completion date
November 24, 2023
Enrollment
72 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease, vaso-occlusive crisis, vaso-occlusive pain episode in sickle cell disease